Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice

Atherosclerosis

Volumn 234, Issue 1, 2014, Pages 237-243

  Liu, Fengming ^a,b,c   Wu, Lin ^b,d   Wu, Gongxiong ^b   Wang, Chun ^d   Zhang, Lining ^a   Tomlinson, Stephen ^e,f   Qin, Xuebin ^b,c  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; CD59 and therapeutics; Complement; Complement regulation; Crry

Indexed keywords

APOLIPOPROTEIN E; BIOTIN; CD59 ANTIGEN; CHOLESTEROL; COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; CR2 CRRY; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CR2-CRRY FUSION PROTEIN, MOUSE; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA ROOT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DRUG CONJUGATION; GENE OVEREXPRESSION; LIPID DIET; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; FEMALE; MALE;

ANIMALS; ATHEROSCLEROSIS; COMPLEMENT INACTIVATING AGENTS; FEMALE; MALE; MICE; RECOMBINANT FUSION PROTEINS;

EID: 84897930284     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.03.004     Document Type: Article

References (30)

1. Hansson G.K., Holm J., Kral J.G. Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions. Acta Pathol Microbiol Immunol Scand A 1984, 92:429-435.
2. Rus H.G., Niculescu F., Constantinescu E., Cristea A., Vlaicu R. Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis 1986, 61:35-42.
3. Wu G., Hu W., Shahsafaei A., et al. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res 2009, 104:550-558.
4. Yun S., Leung V.W., Botto M., Boyle J.J., Haskard D.O. Brief report: accelerated atherosclerosis in low-density lipoprotein receptor-deficient mice lacking the membrane-bound complement regulator CD59. Arterioscler Thromb Vasc Biol 2008, 28:1714-1716.
5. Lewis R.D., Jackson C.L., Morgan B.P., Hughes T.R. The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. Mol Immunol 2010, 47:1098-1105.
6. An G., Miwa T., Song W.L., et al. CD59 but not DAF deficiency accelerates atherosclerosis in female ApoE knockout mice. Mol Immunol 2009, 46:1702-1709.
7. -/- mice. Faseb J 2011, 25:2447-2455.
8. Qin X., Gao B. The complement system in liver diseases. Cell Mol Immunol 2006, 3:333-340.
9. Morgan B.P. Regulation of the complement membrane attack pathway. Crit Rev Immunol 1999, 19:173-198.
10. Medof M.E., Lublin D.M., Holers V.M., et al. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci United States Am 1987, 84:2007-2011.
11. Nicholson-Weller A., Spicer D.B., Austen K.F. Deficiency of the complement regulatory protein, "decay-accelerating factor," on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria. New Engl J Med 1985, 312:1091-1097.
12. Qin X., Miwa T., Aktas H., et al. Genomic structure, functional comparison, and tissue distribution of mouse Cd59a and Cd59b. Mamm Genome 2001, 12:582-589.
13. Baalasubramanian S., Harris C.L., Donev R.M., et al. CD59a is the primary regulator of membrane attack complex assembly in the mouse. JImmunol 2004, 173:3684-3692.
14. Paul M.S., Aegerter M., Cepek K., Miller M.D., Weis J.H. The murine complement receptor gene family. III. The genomic and transcriptional complexity of the Crry and Crry-ps genes. JImmunol 1990, 144:1988-1996.
15. Xu C., Mao D., Holers V.M., Palanca B., Cheng A.M., Molina H. Acritical role for murine complement regulator crry in fetomaternal tolerance. Science 2000, 287:498-501.
16. Dmytrijuk A., Robie-Suh K., Cohen M.H., Rieves D., Weiss K., Pazdur R. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 2008, 13:993-1000.
17. Reid R.R., Prodeus A.P., Khan W., Hsu T., Rosen F.S., Carroll M.C. Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. JImmunol 1997, 159:970-975.
18. Taylor P.R., Carugati A., Fadok V.A., et al. Ahierarchical role for classical pathway complement proteins in the clearance of apoptotic cells invivo. JExp Med 2000, 192:359-366.
19. Atkinson C., Song H., Lu B., et al. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. JClin Invest 2005, 115:2444-2453.
20. He C., Imai M., Song H., Quigg R.J., Tomlinson S. Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. JImmunol 2005, 174:5750-5757.
21. Spitzer D., Unsinger J., Mao D., Wu X., Molina H., Atkinson J.P. Invivo correction of complement regulatory protein deficiency with an inhibitor targeting the red blood cell membrane. JImmunol 2005, 175:7763-7770.
22. Carbone J., Micheloud D., Salcedo M., et al. Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection. Transpl Infect Dis 2008, 10:396-402.
23. Huber-Lang M., Sarma J.V., Zetoune F.S., et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006, 12:682-687.
24. Qiao F., Atkinson C., Song H., Pannu R., Singh I., Tomlinson S. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol 2006, 169:1039-1047.
25. Atkinson C., Qiao F., Song H., Gilkeson G.S., Tomlinson S. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. JImmunol 2008, 180:1231-1238.
26. Lewis R.D., Perry M.J., Guschina I.A., Jackson C.L., Morgan B.P., Hughes T.R. CD55 deficiency protects against atherosclerosis in Apoe-deficient mice via C3a modulation of lipid metabolism. Am J Pathol 2011, 179:1601-1607.
27. Huang Y., Qiao F., Atkinson C., Holers V.M., Tomlinson S. Anovel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. JImmunol 2008, 181:8068-8076.
28. Sekine H., Kinser T.T., Qiao F., et al. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 2011, 63:1076-1085.
29. Song H., Qiao F., Atkinson C., Holers V.M., Tomlinson S. Acomplement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. JImmunol 2007, 179:7860-7867.
30. Wu G., Chen T., Shahsafaei A., et al. Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice. Circulation 2010, 121:1338-1346.